Recently added

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

BAUDIN, Eric; Hörsch, Dieter; Singh, Simron; CAPLIN, MARTYN; Wolin, Edward; Capdevila Castillon, Jaume (Bioscientifica, 2024-07-22)

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Kapiteijn, Ellen; Litière, Saskia; Godbert, Yann; Rodien, Patrice; Leboulleux, Sophie; Schoffski, Patrick; Capdevila Castillon, Jaume (Frontiers Media, 2024-06-27)

Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data

González, Sara; Munté, Elisabet; Feliubadaló, Lidia; del Valle, Jesús; Ramos-Muntada, Mireia; Balmaña, Judith (Elsevier, 2024-08)

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Hamilton, Erika; Oliveira, Mafalda; Turner, Nicholas; GARCIA-CORBACHO, JAVIER; HERNANDO MELIA, CRISTINA; Ciruelos, Eva (Elsevier, 2024-05-08)

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

Sköld, Camilla; Corvigno, Sara; Dahlstrand, Hanna; Enblad, Gunilla; Mezheyeuski, Artur; Sundström Poromaa, Inger (Springer, 2024-04-05)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study ﻿

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF) ﻿

Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data ﻿

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results ﻿

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer ﻿

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer